Sarepta Therapeutics, Inc. (SRPT)
Upgrades & Downgrades
Latest SRPT news
Stock Market Rallies Powerfully Off Lows; Lamb Weston, Sarepta, AMN In Focus | Stock Market Today
5 October 2022
But it's too early to declare a market bottom. Stock Market Today: October 5, 2022 Hosts: Ali Coram & Ken Shreve Get more IBD by subscribing to our channel: https://bit.ly/3OqppAs Visit our website: h...
Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate
30 September 2022
If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.
Sarepta prices almost $1 billion convertible bond offering
14 September 2022
Sarepta Therapeutics Inc. SRPT, -9.77% said Wednesday it has priced $980 million of convertible senior unsecured notes that mature in September of 2027. The company will reduce the potential dilution ...
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
12 September 2022
Sarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on treating DMD. It expects to initiate a BLA filing for its DMD gene therapy by year-end
Sarepta Therapeutics to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
6 September 2022
CAMBRIDGE, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will p...
Why Is Sarepta Therapeutics (SRPT) Up 13.8% Since Last Earnings Report?
1 September 2022
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
30 August 2022
In recent days, biotech stocks have slowed their early-August sprint. But not all shares are ready to hit the showers.
Sarepta: Advancement In DMD Space With SRP-9001 And Licensed MyoAAV
10 August 2022
BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. The global market opportunity f...
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
3 August 2022
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.